Psoriasis and its management

British Medical Journal

Volumn 333, Issue 7564, 2006, Pages 380-384

  Smith, Catherine H ^a   Barker, J N W N ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CALCIPOTRIOL; CALCITRIOL; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; DITHRANOL; EFALIZUMAB; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; PIMECROLIMUS; TACALCITOL; TACROLIMUS; TAR; TAZAROTENE; TUMOR NECROSIS FACTOR; VITAMIN D DERIVATIVE; DERMATOLOGICAL AGENT;

CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC TEST; DRUG MECHANISM; DRUG MONITORING; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; IMMUNE RESPONSE; MORTALITY; PATHOGENESIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; QUALITY OF LIFE; REVIEW; SKIN IRRITATION; SOCIAL PSYCHOLOGY; TOPICAL TREATMENT; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; BIOLOGICAL THERAPY; MENTAL STRESS; METHODOLOGY; SELF CARE;

BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASES; DERMATOLOGIC AGENTS; HUMANS; PHOTOTHERAPY; PSORIASIS; QUALITY OF LIFE; SELF CARE; STRESS, PSYCHOLOGICAL;

EID: 33747597605     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.333.7564.380     Document Type: Review

References (25)

1. Bowcock AM, Krueger JG. Getting under the skin: the immuriogenetics of psoriasis. Nature 2005;5:699-711.
2. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113: 1664-75.
3. Boyman O, Hefti HB, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004;199:731-6.
4. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1333-5.
5. Harlow D, Poyner T, Finlay AY, Dykes PJ. Impaired quality of life of adults with skin disease in primary care. Br J Dermatol 2000;143:979-82.
6. Fortune DG, Richards HL, Griffiths CEM. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 2005;23:681-94.
7. DeKorte J, Sprangers MA, Members FM, Bos JD. Quality of life in patients with psoriasis: a systemic literature review. J Investig Dermatol Symp Proc 2005;9:140.
8. Rapp SR, Feldman SR, Exum ML. Psoriasis causes as much distress as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.
9. Stern RS, Nijsten T, Feldman SR. Psoriasis is common, carries a substantial burden even when noi extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9:136-9.
10. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-30.
11. Boffetta P. Cancer risk in a population-based cohort of patients hospitalised for psoriasis in Sweden. J Invest Dermatol 2001;117:1531-7.
12. Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000;114:587-90.
13. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425-9.
14. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999;135:1490-3.
15. Lebowohl M, Callen JP. Obesity, smoking and psoriasis. JAMA 2006; 290:208-10.
16. Chalmers RJG, O'Sullivan T, Oven CM, Griffiths CEM. Interventions for guttate psoriasis. Cochrane Database Syst Rev 2000;(2):CD001213.
17. Owen CM, Chalmers RJG, O'Sullivan T, Griffiths CEM. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst Rev 2000;(2):CD001976.
18. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002;146;351-64.
19. Ashcroft DM, Li Wan PA, Williams HC, Griffiths CEM. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000;320:963-7.
20. Griffiths CE, Clark CM, Chalmers RJ, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4;1-125.
21. Heyandael VM, Spuls PI, Opmeer BC, de Borgie CAJM, Reitsma JB, Godschmidt WFM, et al. Methotrexate versus cyclosporine in moderate to severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65.
22. Chalmers RJG, Kirby B, Smith A, Burrows P, Little R, Horan M, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005;152:444-50.
23. Maurice PDL, Maddox AJ, Green CA, Tatnall F, Schofield JK, Stott DJ. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol 2005;152:451-8.
24. Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJG, Chandler D, et al. British Association of Dermatologists guidelines for use ol biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486-97.
25. Salisbury C, Noble A, Horrocks S, Crosby Z, Harrison V, Coast J, et al. Evaluation of a general practitioner with special interest service for dermatology: randomised controlled trial. BMJ 2005;331:1441-6.